Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase dataFierce BiotechMay 11, 02:06 PM
Odyssey’s CEO sees $304M IPO as chance to create a ‘little large pharma’Fierce BiotechMay 8, 11:27 AM
Entrada's stock craters as DMD data underperform expectations, handing advantage to NovartisFierce BiotechMay 7, 01:12 PM
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposalFierce BiotechApr 30, 05:48 PM
FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on boardFierce BiotechApr 28, 05:52 PM
Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecastsFierce BiotechApr 27, 01:51 PM
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?Fierce BiotechApr 24, 01:30 PM
AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plansFierce BiotechApr 17, 07:00 PM
UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicineFierce BiotechApr 17, 05:55 PM
Kailera CEO 'knew we were in a good spot' before obesity biotech's record-breaking $625M IPOFierce BiotechApr 17, 08:42 AM
FDA urges clinical trial sponsors to report the results of their studiesFierce BiotechApr 13, 07:03 PM
Allogene’s off-the-shelf CAR-T erases lingering lymphoma cells in early slice of dataFierce BiotechApr 13, 11:45 AM
Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole storyFierce BiotechApr 1, 07:00 PM
AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flopsFierce BiotechMar 27, 09:58 AM